engleski

Superior mesenteric vein occlusion in rats induced portal and caval hypertension, aortic hypotension, and peaked P waves, tachycardia. Therapy with pentadecapeptide BPC 157. Bypassing pathway to circumvent venous occlusion

Aim. We introduce pentadecapeptide BPC 157 therapy in rats with superior mesenteric vein (SMV) occlusion, 15 min. SMV occlusion was at the point cranially to entry of inferior anterior pancreaticodudenal vein (IAPDV), caudally to entry of inferior mesenteric vein (IMV). We counteracted thrombosis in portal vein (PV), inferior caval vein (ICV), superior mesenteric vein (SMV), lienal vein (LV). We counteracted the severe venous hypertension (PV, SMV, ICV) and aortal hypotension (assessed as described Vascul Pharmacol 2018 ; 106:54- 66), peaked P waves and tachycardia, and revealed promotion of vessels recruitment to circumvent occlusion, and reestablish blood flow continuity, bypassing pathway SMV-middle colic vein (MCV)-IMV-SMV-PV (assessed by SMV venography, bellow ligation as described Vascul Pharmacol 2018 ; 106:54-66). We counteracted oxidative stress in tissue (cecum, assessment by thiobarbituric acid reactivity (TBARS)). Recently, in rats with portal triad obstruction, BPC 157 counteracts portal hypertension and caval hypotension (Gastroenterology 2015, Vol. 148, Issue 4, S- 650) ; portal and caval hypertension in rats with suprahepatic occlusion of ICV (Gastroenterology, Vol. 154, Issue 6, Suppl 1, s-532) ; portal hypertension in bile duct ligated rats (Gastroenterology 154, Issue 6, Suppl 1, s-536) ; caval hypertension and aortal hypotension and ICV thrombosis after infrarenal ICV occlusion (Vascul Pharmacol 2018 ; 106:54-66). Likewise, BPC 157 counteracts various lesions in the whole GI-tract and free radicals formation (Curr Pharm Des 2018 ; 24:1990-2001). Methods: Medication (/kg) (BPC 157 (10 μg, 10 ng), or saline (5 ml) (controls)) was applied as an abdominal bath immediately after SMV occlusion. Results: At the end of the 15 min, rats with SMV occlusion exhibit huge SMV, PV, and ICV hypertension, mild aortic hypotension (controls, means±SD mmHg, 59±4 (PV), 30±4 (SMV), 43±4 (ICV), 80±3 (abdominal aorta)) and marked thrombosis (cloth weight, g), 0.0039±0.0009 ICV, 0.082±0.009 PV, 0.0022±0.0009 SMV, 0.0031±0.0008 LV), unless BPC 157 was given (10 μg: 59±4 (PV), 30±4 (SMV), 43±4 (ICV), 80±3 (abdominal aorta), cloth weight, g, 0.0018±0.0005 ICV, 0.041±0.007 PV, 0.0011±0.0005 SMV, 0.0015±0.0006 LV), (*P≤0.05, at least vs. control), along with less oxidative stress. All control rats with SMV occlusion exhibit peaked P waves and tachycardia. SMV venography bellow ligation documented full congestion of the caudal part of SMV and its tributaries, but no bypassing pathway. Contrarily, SMV venography bellow ligation documented along with BPC 157 administration rapid presentation of the bypassing pathway SMV-MCV-IMV-SMV-PV ; ECG changes were absent in all BPC 157-rats (Fisher exact probability test P≤0.05 vs. control) (Fig. 1, Fig. 2). Conclusion. BPC 157 therapy successfully counteracts the adverse effects of the SMV occlusion.

BPC 157 ; superior mesenteric vein ; aortic hypotension

nije evidentirano